Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2022-08-19 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
监事会关于公司2022年限制性股票激励计划及相关事项的核查意见
Share Issue/Capital Change Classification · 95% confidence The document is a supervisory board opinion on the company's 2022 restricted stock incentive plan and related matters. It discusses compliance with relevant laws and regulations, the scientific and reasonable setting of performance indicators, and the benefits of the incentive plan for the company and shareholders. The document is relatively short (1464 characters) and focuses on the approval and verification of a stock incentive plan rather than financial results or detailed financial statements. It does not contain financial data or earnings information, nor is it a regulatory announcement or a report publication notice. The content aligns with disclosures related to share-based compensation plans and capital changes, specifically the issuance of restricted stock as part of an incentive plan. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2022-08-19 Chinese
益丰药房第四届监事会第十四次会议
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company 益丰大药房连锁股份有限公司. It details the convening and voting results of the 14th meeting of the 4th Supervisory Board, including approval of a restricted stock incentive plan and related management measures. The document is a formal announcement of board meeting decisions rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a regulatory certification or a report publication notice. It fits best under Board/Management Information (MANG) as it relates to governance decisions and internal company management resolutions.
2022-08-19 Chinese
益丰药房关于独立董事公开征集委托投票权的公告
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a public announcement by an independent director soliciting proxy voting rights from shareholders for specific agenda items related to a 2022 restricted stock incentive plan to be discussed at the company's third extraordinary general meeting (EGM) scheduled for September 5, 2022. It includes details about the voting period, procedures for submitting proxy authorization, and the director's voting stance. The document does not contain financial statements or detailed financial analysis but is focused on the solicitation of voting rights for shareholder meeting agenda items. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document length is 4220 characters, which is consistent with a detailed proxy solicitation notice rather than a full report or announcement of a report publication.
2022-08-19 Chinese
益丰药房关于召开2022年第三次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2022 third extraordinary general meeting of shareholders for Yifeng Pharmacy Chain Co., Ltd. It includes details about the meeting date, voting methods, agenda items related to a 2022 restricted stock incentive plan, and instructions for shareholders. The document is a formal announcement of the meeting and related procedural information, not the actual meeting minutes or voting results. It does not contain financial statements or detailed financial data. The document length is 3276 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2022-08-19 Chinese
益丰药房独立董事关于第四届董事会第十五次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion statement from the independent directors of 益丰大药房连锁股份有限公司 regarding the company's proposed public issuance of convertible bonds, the use of previously raised funds, measures to mitigate dilution of immediate returns, and a three-year shareholder return plan. It references compliance with Chinese securities laws, stock exchange listing rules, and regulatory guidelines. The document is a formal opinion on financing and capital raising activities, specifically the issuance of convertible bonds, and includes analysis and approval recommendations. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report or Interim Report. It is not a simple announcement or certification but a detailed independent opinion on a capital raising proposal. Therefore, the document best fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive content beyond a mere announcement, so it is not a Report Publication Announcement (RPA).
2022-08-10 Chinese
益丰药房第四届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 15th meeting of the 4th Board of Directors of Yifeng Pharmacy Chain Co., Ltd. It includes extensive information about the company's plan to publicly issue convertible bonds, including terms, conditions, voting results, and related procedural details. The document is a formal board meeting resolution announcement, with no actual financial statements or comprehensive financial performance data. It is not an earnings release, annual report, or interim report. The content focuses on board decisions and approvals, which fits the category of Board/Management Information (MANG). The document length is substantial and contains detailed board meeting content, not just a brief announcement or a report publication notice. Therefore, the appropriate classification is MANG with high confidence.
2022-08-10 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.